Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.07 +4.11%
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.
GUIDANCE:
Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
